Notably, overexpression of DLL3 was associated with shorter overall survival (OS) in endometrial cancer (Wang et al., 2018), ovarian cancer (Jia et al., 2019), breast cancer (Yuan et al., 2021) and small-cell bladder cancer (Koshkin et al., 2019). Here, DLL3 is linked to endometrial cancer.